The pro-metastasis tyrosine phosphatase, PRL-3 (PTP4A3), is a novel mediator of oncogenic function of BCR-ABL in human chronic myeloid leukemia

Molecular Cancer

Volumn 11, Issue , 2012, Pages

  Zhou, Jianbiao ^a   Cheong, Lip Lee ^b   Liu, Shaw Cheng ^a   Chong, Phyllis S Y ^a   Mahara, Sylvia ^a   Bi, Chonglei ^a   Ong, Kelly O K ^a   Zeng, Qi ^d   Chng, Wee Joo ^a,b,c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b Dept Medicine Endocrinol Diabet   (Singapore)

^c NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^d INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

Author keywords

BCR ABL; Chronic myeloid leukemia (CML); Imatinib; Protein tyrosine phosphatase of regenerating liver 3 (PRL 3); PTP4A3; Tyrosine kinase inhibitor (TKI)

Indexed keywords

BCR ABL PROTEIN; IMATINIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PRL 3 PROTEIN; PROTEIN TYROSINE KINASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ARTICLE; CANCER RESISTANCE; CELL PROLIFERATION; CELL RENEWAL; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOLOGY; GENE SILENCING; HUMAN; HUMAN CELL; METASTASIS; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION; GENE EXPRESSION REGULATION, LEUKEMIC; GENE SILENCING; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NEOPLASM METASTASIS; NEOPLASM PROTEINS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN TYROSINE PHOSPHATASES; PYRIMIDINES; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS;

EID: 84866483681     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-11-72     Document Type: Article

References (25)

1. Van Etten RA. Mechanisms of transformation by the BCR-ABL oncogene: new perspectives in the post-imatinib era. Leuk Res 2004, 28(Suppl 1):S21-S28.
2. Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood 2008, 112:4808-4817. 10.1182/blood-2008-07-077958, 19064740.
3. Radich JP. Chronic myeloid leukemia 2010: where are we now and where can we go?. Hematology Am Soc Hematol Educ Program 2010, 2010:122-128. 10.1182/asheducation-2010.1.122, 21239781.
4. Hochhaus A. First-Line management of CML: a state of the art review. J Natl Compr Canc Netw 2008, 6(Suppl 2):S1-S10.
5. Druker BJ, Sawyers CL, Capdeville R, Ford JM, Baccarani M, Goldman JM. Chronic myelogenous leukemia. Hematology (Am Soc Hematol Educ Program) 2001:87-112.
6. Hantschel O, Superti-Furga G. Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat Rev Mol Cell Biol 2004, 5:33-44. 10.1038/nrm1280, 14708008.
7. Sattler M, Griffin JD. Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin Hematol 2003, 40:4-10.
8. La Rosee P, Deininger MW. Resistance to imatinib: mutations and beyond. Semin Hematol 2010, 47:335-343. 10.1053/j.seminhematol.2010.06.005, 20875550.
9. Melo JV, Chuah C. Novel agents in CML therapy: tyrosine kinase inhibitors and beyond. Hematology Am Soc Hematol Educ Program 2008:427-435.
10. Roumiantsev S, Shah NP, Gorre ME, Nicoll J, Brasher BB, Sawyers CL, Van Etten RA. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc Natl Acad Sci U S A 2002, 99:10700-10705. 10.1073/pnas.162140299, 125018, 12149456.
11. Bessette DC, Wong PC, Pallen CJ. PRL-3: a metastasis-associated phosphatase in search of a function. Cells Tissues Organs 2007, 185:232-236. 10.1159/000101324, 17587829.
12. Basak S, Jacobs SB, Krieg AJ, Pathak N, Zeng Q, Kaldis P, Giaccia AJ, Attardi LD. The metastasis-associated gene Prl-3 is a p53 target involved in cell-cycle regulation. Mol Cell 2008, 30:303-314. 10.1016/j.molcel.2008.04.002, 18471976.
13. Winter-Vann AM, Casey PJ. Post-prenylation-processing enzymes as new targets in oncogenesis. Nat Rev Cancer 2005, 5:405-412. 10.1038/nrc1612, 15864282.
14. Al-Aidaroos AQ, Zeng Q. PRL-3 phosphatase and cancer metastasis. J Cell Biochem 2010, 111:1087-1098. 10.1002/jcb.22913, 21053359.
15. Stephens BJ, Han H, Gokhale V, Von Hoff DD. PRL phosphatases as potential molecular targets in cancer. Mol Cancer Ther 2005, 4:1653-1661. 10.1158/1535-7163.MCT-05-0248, 16275986.
16. Saha S, Bardelli A, Buckhaults P, Velculescu VE, Rago C, St Croix B, Romans KE, Choti MA, Lengauer C, Kinzler KW, Vogelstein B. A phosphatase associated with metastasis of colorectal cancer. Science 2001, 294:1343-1346. 10.1126/science.1065817, 11598267.
17. Fagerli UM, Holt RU, Holien T, Vaatsveen TK, Zhan F, Egeberg KW, Barlogie B, Waage A, Aarset H, Dai HY, et al. Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells. Blood 2008, 111:806-815. 10.1182/blood-2007-07-101139, 2200854, 17934070.
18. Wang H, Vardy LA, Tan CP, Loo JM, Guo K, Li J, Lim SG, Zhou J, Chng WJ, Ng SB, et al. PCBP1 suppresses the translation of metastasis-associated PRL-3 phosphatase. Cancer Cell 2010, 18:52-62. 10.1016/j.ccr.2010.04.028, 20609352.
19. Zhou J, Bi C, Chng WJ, Cheong LL, Liu SC, Mahara S, Tay KG, Zeng Q, Li J, Guo K, et al. PRL-3, a metastasis associated tyrosine phosphatase, is involved in FLT3-ITD signaling and implicated in anti-AML therapy. PLoS One 2011, 6:e19798. 10.1371/journal.pone.0019798, 3093398, 21589872.
20. Beekman R, Valkhof M, Erkeland SJ, Taskesen E, Rockova V, Peeters JK, Valk PJ, Lowenberg B, Touw IP. Retroviral Integration Mutagenesis in Mice and Comparative Analysis in Human AML Identify Reduced PTP4A3 Expression as a Prognostic Indicator. PLoS One 2011, 6:e26537. 10.1371/journal.pone.0026537, 3197662, 22028901.
21. Guo K, Li J, Tang JP, Tan CP, Hong CW, Al-Aidaroos AQ, Varghese L, Huang C, Zeng Q. Targeting intracellular oncoproteins with antibody therapy or vaccination. Sci Transl Med 2011, 3:99ra85. 10.1126/scitranslmed.3002296, 21900592.
22. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005, 353:172-187. 10.1056/NEJMra044389, 16014887.
23. Hehlmann R, Hochhaus A, Baccarani M. Chronic myeloid leukaemia. Lancet 2007, 370:342-350. 10.1016/S0140-6736(07)61165-9, 17662883.
24. Scherr M, Battmer K, Winkler T, Heidenreich O, Ganser A, Eder M. Specific inhibition of bcr-abl gene expression by small interfering RNA. Blood 2003, 101:1566-1569. 10.1182/blood-2002-06-1685, 12393533.
25. Juric D, Lacayo NJ, Ramsey MC, Racevskis J, Wiernik PH, Rowe JM, Goldstone AH, O'Dwyer PJ, Paietta E, Sikic BI. Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias. J Clin Oncol 2007, 25:1341-1349. 10.1200/JCO.2006.09.3534, 17312329.